Q1 2026 Earnings Call May 5, 2026 4:30 PM EDTCompany ParticipantsRaymond Furey - Executive VP, Chief Compliance ...

Q1 2026 Management View “In the first quarter of 2026, we generated net product sales of just under $55 million, representing a 26% growth compared to the first quarter of 2025.” (President, CEO & ...

Rigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from ...

Rigel Pharmaceuticals (NASDAQ:RIGL) reported first-quarter 2026 results that management said reflected continued ...

Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous ...

Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) jumped 20.9% in August, according to data provided by S&P Global Market Intelligence as investors in the biotech become more comfortable with the ...

NEW YORK (AP) -- Shares of Rigel Therapeutics Inc. lost more than a third of their value Friday on mixed results from a late-stage clinical trial of a rheumatoid arthritis drug the company helped ...

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...